nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.02.2011 | General Gynecology

Oxidant/antioxidant status in premenstrual syndrome

verfasst von: Candan Iltemir Duvan, Ahmet Cumaoglu, Nilgun Ozturk Turhan, Cimen Karasu, Hasan Kafali

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate oxidant/antioxidant status in premenstrual syndrome (PMS).

Methods

Study group (n = 20) consisted of PMS and control group (n = 21) consisted of normal menstruating women. The serum oxidant status was assessed by the lipid hydroperoxide (LHP), malondialdehyde (MDA) and protein carbonyl (PC); the antioxidant status was assessed by the total thiol (T-SH) and total antioxidant capacity (TAC).

Results

The study and control groups revealed no statistical difference, in terms of day 3 LHP, MDA, PC, T-SH and TAC levels. There were no significant differences between groups in terms of day 21 MDA, PC and T-SH levels. However, day 21 LHP levels were increased and TAC levels were decreased in the study group compared with the control group.

Conclusion

Increased oxidative stress and reduced antioxidant capacity may occur in PMS. It can be speculated that the imbalance of oxidant/antioxidant systems may be a cause or the consequence of the various stress symptoms in PMS.

Freeman EW (2003) Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28:25–37CrossRefPubMed

Halbreich U (2004) The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder-clinical procedures and research perspectives. Gynecol Endocrinol 19:320–334CrossRefPubMed

Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C et al (2006) Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health 15:57–69CrossRef

Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28:1–23

Alpay FB, Turhan NO (2001) Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. Int J Fertil Womens Med 46:228–231PubMed

Halbreich U (2003) The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 28:55–99CrossRef

Kendler KS, Karkowski LM, Corey LA, Neale MC (1998) Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 155:1234–1240PubMed

Reame NE, Marshall JC, Kelch RP (1992) Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle. Psychoneuroendocrinology 17:205–213CrossRefPubMed

Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I et al (2003) Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci 1007:42–53CrossRefPubMed

10.

Evans MD, Dizdaroglu M, Cooke MS (2004) Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567:1–61CrossRefPubMed

11.

Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29–38CrossRefPubMed

12.

Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003) Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8:365–370CrossRefPubMed

13.

Arranz L, Guayerbas N, De la Fuente M (2007) Impairment of several immune functions in anxious women. J Psychosom Res 62:1–8CrossRefPubMed

14.

Harma M, Harma M, Erel O (2005) Measurement of the total antioxidant response in preeclampsia with a novel automated method. Eur J Obstet Gynecol Reprod Biol 118:47–51CrossRefPubMed

15.

Harma M, Harma M, Kocyigit A (2004) Comparison of protein carbonyl and total plasma thiol concentrations in patients with complete hydatidiform mole with those in healthy pregnant women. Acta Obstet Gynecol Scand 83:857–860PubMed

16.

Lagod L, Paszkowski T, Sikorski R, Rola R (2001) The antioxidant prooxidant balance in pregnancy complicated by spontaneous abortion. Ginekol Pol 72:1073–1078PubMed

17.

Freemen E, Rickels K, Sondheimer SJ, Polansky M (1990) Ineffectiveness of progesteron suppository treatment for premenstrual syndrome. JAMA 264:349–353CrossRef

18.

Zadeh-Nourooz J, Tajaddini-Sarmadi J, Wolff S (1994) Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 220:403–409CrossRef

19.

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefPubMed

20.

Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205CrossRefPubMed

21.

Benzie IF, Strain JJ (1999) Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Method Enzymol 299:15–27CrossRef

22.

Korzekwa MI, Steiner M (1997) Premenstrual syndromes. Clin Obstet Gynecol 40:564–576CrossRefPubMed

23.

Kalia G, Sudheendran S, Rao A (2001) Antioxidant status and lipid peroxidation in premenstrual syndrome: a preliminary study. Clin Chim Acta 309:97–99CrossRefPubMed

24.

Balat O, Dikensoy E, Ugur MG, Atmaca R, Cekmen M, Yurekli M (2007) Malon dialdehyde, nitrite and adrenomedullin levels in patients with premenstrual syndrome. Arch Gynecol Obstet 275:361–365CrossRefPubMed

25.

Bäckström T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J (1983) Mood, sexuality, hormones, and the menstrual cycle II: hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 45:503–507PubMed

26.

Halbreich U, Endicott J, Goldstein S, Nee J (1986) Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 74:576–586CrossRefPubMed

27.

Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW et al (2000) SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47:96–106CrossRefPubMed

28.

Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM (2003) Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry 54:757–762CrossRefPubMed

29.

Rammal H, Bouayed J, Younos C, Soulimani R (2008) Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav Immun 22:1156–1159CrossRefPubMed

Titel: Oxidant/antioxidant status in premenstrual syndrome
verfasst von: Candan Iltemir Duvan
Ahmet Cumaoglu
Nilgun Ozturk Turhan
Cimen Karasu
Hasan Kafali
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-1347-y

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Erratum to: Cephalothoracopagus, janiceps, disymmetros, monoomphalian conjoined twins undiagnosed until early second trimester

Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

Risk factors in prolonged postpartum urinary retention: an analysis of six cases

Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV− mothers: a meta-analysis